SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2025

SEGMENT INFORMATION

Schedule of segment information

	Years ended December 31,
	2025			2024
	(amounts, in thousands)
Revenue	$	37,063		$	35,595
Gross profit	$	26,491		$	24,887
Gross margin		71	%		70	%
Total operating expenses	$	41,240		$	41,339
Loss from operations		(14,749)			(16,452)
EBITDA and Adjusted EBITDA (both non-GAAP measures):
Net loss	$	(8,198)		$	(20,719)
Interest expense, net		2,612			1,399
Benefit from income taxes		(401)			(1,691)
Depreciation and amortization expense		1,496			1,570
Earnings (Loss) before interest expense, income taxes, depreciation and amortization (“EBITDA”), a non-GAAP measure		(4,491)			(19,441)
Stock-based compensation		2,765			3,760
(Gain) loss on foreign currency transactions		(9,321)			4,225
Restructuring		510			—
Adjusted EBITDA, a non-GAAP measure	$	(10,537)		$	(11,456)
Adjusted net loss, a non-GAAP measure:
Net loss	$	(8,198)		$	(20,719)
Stock-based compensation		2,765			3,760
Gain (loss) on foreign currency transactions		(9,321)			4,225
Restructuring		510			—
Adjusted net loss, a non-GAAP measure	$	(14,244)		$	(12,734)
Total cash used in operating and investing activities	$	(12,749)		$	(15,097)
Total Assets	$	44,182		$	47,372

	Years ended December 31,
	2025		2024
	(amounts, in thousands)
Research and development, net of grant income:
Clinical expenses	$	3,377	$	4,979
Other research and development expenses		1,708		2,628
Total research and development, net of grant income	$	5,085	$	7,607
Selling, general and administrative
Royalty expense		1,097		1,869
Stock-based compensation		2,237		2,830
Legal, financial and consulting		4,108		3,179
Other general and administrative		28,203		25,854
Total selling, general and administrative	$	35,645	$	33,732